At Erasca, our mission is embedded in our name: To erase cancer. Energized by recent scientific discoveries in drugging various biological drivers of cancer, we are advancing multiple programs that shut down key cancer pathways in order to solve oncology's hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. We also are pursuing additional pipeline expansion opportunities through academic and biopharmaceutical collaborations.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/27/20 | $200,000,000 | Series B |
ARCH Venture Partners City Hill Ventures Colt Ventures Cormorant Asset Management EDBI Invus LifeSci Venture Partners Terra Magnum Capital Partners | undisclosed |
| 08/31/20 | $36,000,000 | Series B Extension |
OrbiMed Advisors Partner Fund Management | undisclosed |
